SGCG and colorectal carcinoma: These data should drive studies of the effect of pharmacological manipulation of type II IL-4R signalling in animal models of different stages of colorectal carcinogenesis with a view to determining the risk/benefit balance of targeting the IL-4R in different patient populations at risk of, or with established, CRC.